ABVC BioPharma (ABVC) Competitors $2.85 +0.08 (+2.89%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.85 0.00 (0.00%) As of 09/12/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. RNAC, JBIO, ALLO, FENC, ENGN, TNXP, PRQR, IMMP, SGMT, and HUMAShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Cartesian Therapeutics (RNAC), Jade Biosciences (JBIO), Allogene Therapeutics (ALLO), Adherex Technologies (FENC), enGene (ENGN), Tonix Pharmaceuticals (TNXP), ProQR Therapeutics (PRQR), Prima BioMed (IMMP), Sagimet Biosciences (SGMT), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors Cartesian Therapeutics Jade Biosciences Allogene Therapeutics Adherex Technologies enGene Tonix Pharmaceuticals ProQR Therapeutics Prima BioMed Sagimet Biosciences Humacyte Cartesian Therapeutics (NASDAQ:RNAC) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Is RNAC or ABVC more profitable? Cartesian Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. Cartesian Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% ABVC BioPharma -963.46%-46.76%-23.02% Which has better valuation and earnings, RNAC or ABVC? ABVC BioPharma has lower revenue, but higher earnings than Cartesian Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$1.03M245.32-$77.42M-$52.83-0.18ABVC BioPharma$391.24K171.49-$4.90M-$0.17-16.76 Do analysts rate RNAC or ABVC? Cartesian Therapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 313.22%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor RNAC or ABVC? In the previous week, Cartesian Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for ABVC BioPharma. Cartesian Therapeutics' average media sentiment score of 1.58 beat ABVC BioPharma's score of 0.95 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RNAC or ABVC? Cartesian Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Do insiders and institutionals hold more shares of RNAC or ABVC? 86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCartesian Therapeutics beats ABVC BioPharma on 14 of the 16 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.21M$3.20B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-16.7621.4375.3425.98Price / Sales171.49430.69514.97181.19Price / CashN/A46.6837.5660.44Price / Book47.509.6112.156.29Net Income-$4.90M-$53.29M$3.29B$271.07M7 Day Performance7.55%0.13%0.75%3.87%1 Month Performance-4.04%5.61%4.82%4.88%1 Year Performance310.60%10.49%60.59%26.12% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.6941 of 5 stars$2.85+2.9%N/A+312.9%$65.21M$391.24K-16.7630RNACCartesian Therapeutics2.4627 of 5 stars$9.84-2.1%$40.00+306.5%-39.8%$255.84M$38.91M-0.1964Positive NewsJBIOJade Biosciences2.7344 of 5 stars$7.62-3.5%$16.00+110.0%N/A$248.62MN/A-0.2520ALLOAllogene Therapeutics3.0125 of 5 stars$1.12-0.9%$8.44+654.0%-57.5%$248.51M$20K-1.01310Analyst DowngradeFENCAdherex Technologies2.5003 of 5 stars$8.91+0.5%$13.33+49.6%+62.5%$247.79M$47.54M-21.2110Positive NewsENGNenGene2.6518 of 5 stars$4.80+3.9%$23.29+385.1%-14.1%$245.28MN/A-2.9131Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionTNXPTonix Pharmaceuticals3.283 of 5 stars$27.66-6.6%$70.00+153.1%+79.1%$242.58M$10.09M-0.7050Gap DownPRQRProQR Therapeutics2.8102 of 5 stars$2.29+1.8%$8.00+249.3%+18.4%$240.93M$20.46M-4.98180News CoverageShort Interest ↑IMMPPrima BioMed1.4633 of 5 stars$1.64+1.9%$7.00+326.8%-37.6%$240.74M$5.14M0.002,021News CoveragePositive NewsSGMTSagimet Biosciences3.219 of 5 stars$7.36-2.0%$25.67+248.7%+98.8%$239.35M$2M-4.028Analyst DowngradeHUMAHumacyte3.0068 of 5 stars$1.51-2.6%$9.75+545.7%-73.8%$239.14M$818K-3.36150Positive News Related Companies and Tools Related Companies Cartesian Therapeutics Competitors Jade Biosciences Competitors Allogene Therapeutics Competitors Adherex Technologies Competitors enGene Competitors Tonix Pharmaceuticals Competitors ProQR Therapeutics Competitors Prima BioMed Competitors Sagimet Biosciences Competitors Humacyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVC Stock Alerts